Results 61 to 70 of about 687 (166)

Dermatologic manifestations of hereditary hemochromatosis: A systematic review

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 5, Page 976-986, May 2025.
Abstract Hereditary hemochromatosis (HH) is a genetic disorder leading to excessive iron absorption, impacting multiple organs, notably the skin, nails and mucosae. The objective of this study is to elucidate the dermatologic manifestations, associated symptoms, pathophysiology and management recommendations of HH.
Hossein Akbarialiabad, Parnian Jamshidi, Jeffrey P. Callen, Dédée F. Murrell   +3 more
wiley   +1 more source

Association of Alopecia Universalis, Generalized Vitiligo, and Graves' Disease

Journal of Research in Medical Sciences, 2005
We present a 21-years old woman with alopecia universalis, generalized vitiligo, and Graves' disease. She had had thyroidectomy in early childhood and was receiving replacement therapy with levothyroxine.
Z Shahmoradi, Afshin Darougheh, S Misaghian   +2 more
doaj  

Alopecia universalis with twenty-nail dystrophy (trachyonychia)

Dermatology Online Journal, 2008
A 43-year-old man presented with long-standing trachyonychia of all 20 nails, which worsened after the onset of alopecia universalis 18 months ago. Trachyonychia can be associated with alopecia universalis although the treatment strategies of both conditions differ.
Jr, Peter Chien, Kovich, Olympia I
openaire   +5 more sources

Efficacy and Safety of Long‐Term Azathioprine Therapy for Severe Alopecia Areata: A 10‐Year Cohort Study

Journal of Cosmetic Dermatology, Volume 24, Issue 5, May 2025.
ABSTRACT Background Alopecia areata is an autoimmune disease in which T cells may play a key role in its pathogenesis. Various immunosuppressive drugs have been employed with varying degrees of success. Objectives This study aimed to evaluate the long‐term efficacy and safety of azathioprine as a systemic monotherapy for moderate to severe alopecia ...
Susan Farshi, Parvin Mansouri
wiley   +1 more source

Bimatoprost in the treatment of eyelash universalis alopecia areata

International Journal of Trichology, 2010
To evaluate topical bimatoprost for eyelash growth in patients with alopecia areata (AA).A 1-year retrospective study, bilateral eyelash alopecia.Forty-one subjects with AA universalis without ocular disease applied 0.03% bimatoprost to the eyelid margin once a day over the course of 1 year.Thirty-seven subjects completed the study, one patient was ...
Teresa Ojeda Vila, Francisco Camacho Martínez   +1 more
openaire   +3 more sources

Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar

Immunity, Inflammation and Disease, Volume 13, Issue 4, April 2025.
This study investigates the risk of serious infections (SIs) in patients treated with biologic or targeted‐synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) in Qatar. Out of 1092 patients, 86 (7.9%) experienced SIs, with adalimumab and infliximab associated with higher SI rates.
Sreethish Sasi, Hamad Abdel Hadi, Masautso Chaponda, Reem El Ajez, Mohamed Ataelmanan, Sief Khasawneh, Hind Saqallah, Maisa Ali, Nabeel Abdulla, Javed Iqbal, Ali S. Omrani, Muna Al Maslamani, Abdullatif Al‐Khal   +12 more
wiley   +1 more source

Treatment outcomes and considerations for topical immunotherapy in patients with alopecia totalis and alopecia universalis

Frontiers in Medicine
BackgroundAlopecia areata (AA) is a chronic immune-mediated disorder causing non-scarring hair loss. Severe forms like alopecia totalis (AT) and alopecia universalis (AU) pose therapeutic difficult situations.
Taiyo Hitaka, Sanehito Haruyama, Shun Ohmori, Natsuko Saito-Sasaki, Etsuko Okada, Motonobu Nakamura, Yu Sawada   +6 more
doaj   +1 more source

Alopecia universalis and onychodystrophy during treatment with adalimumab

Baylor University Medical Center Proceedings, 2020
Alopecia universalis, the complete loss of body hair, during anti-tumor necrosis factor-alpha (TNF-α) biologic therapy is a rare occurrence that has infrequently been reported in the literature. In this case, a 50-year-old man with psoriatic arthritis exhibited alopecia universalis with concomitant onychodystrophy 3 months after initiation with ...
Ronnie Youssef, Saadeddine Saad, Sophia Hendrick   +2 more
openaire   +4 more sources

Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year

Journal of the European Academy of Dermatology and Venereology, Volume 39, Issue 6, Page e490-e492, June 2025.
Arash Mostaghimi, Matthias Augustin, Kazutoshi Harada, Maryanne Senna, Yves Dutronc, Guanglei Yu, Susan Ball, Mwangi Murage, Jill Kolodsick, Yiying Brogan, Brett King   +10 more
wiley   +1 more source

Effective management Alopecia totalis by Ayurveda – A case report

Journal of Ayurveda and Integrative Medicine, 2023
Alopecia areata (AA) is a T-cell-mediated autoimmune illness characterized by intermittent, non-scarring hair loss, Alopecia totalis(AT) is a type of AA characterized by total hair loss on the face and scalp.
Shivanand B. Patil, Giramalla S. Patil, Vijay Patil   +2 more
doaj